Sutro Biopharma, Inc. is a high-risk pharmaceutical company based in the United States. Specializing in ESG-focused drug discovery and development, Sutro Biopharma manufactures innovative protein therapeutics for cancer and autoimmune disorders. Their products, including STRO-001 and STRO-002, cater to patients with multiple myeloma, non-Hodgkin lymphoma, ovarian, and endometrial cancers.